Press coverage about Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio-Rad Laboratories, Inc. Class A Common Stock earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 46.7164421507989 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Bio-Rad Laboratories, Inc. Class A Common Stock stock opened at $316.56 on Friday. The company has a quick ratio of 3.17, a current ratio of 4.50 and a debt-to-equity ratio of 0.09. The company has a market cap of $9.53 billion, a P/E ratio of 77.21, a price-to-earnings-growth ratio of 3.50 and a beta of 0.98. Bio-Rad Laboratories, Inc. Class A Common Stock has a 52 week low of $208.95 and a 52 week high of $345.15.

Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) last announced its earnings results on Tuesday, August 7th. The medical research company reported $1.64 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.37. The company had revenue of $575.91 million during the quarter, compared to the consensus estimate of $551.05 million. Bio-Rad Laboratories, Inc. Class A Common Stock had a return on equity of 4.23% and a net margin of 44.77%. equities analysts predict that Bio-Rad Laboratories, Inc. Class A Common Stock will post 6.1 earnings per share for the current fiscal year.

BIO has been the subject of several recent research reports. Zacks Investment Research downgraded Bio-Rad Laboratories, Inc. Class A Common Stock from a “strong-buy” rating to a “sell” rating in a research report on Tuesday, May 1st. Jefferies Financial Group boosted their price objective on Bio-Rad Laboratories, Inc. Class A Common Stock from $325.00 to $355.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $311.80.

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Article: How to Use the New Google Finance Tool

Insider Buying and Selling by Quarter for Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Class A Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. Class A Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.